Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis by Mingfeng He, Xue Wu, Li Li, Guangming Yi, Yitian Wang, Hengqiu He, Ying Ye, Ruiqin Zhou, Zaicheng Xu, Zhenzhou Yang

“…In clinical practice, treatment-naïve EGFR-mutant NSCLC patients with asymptomatic BMs tend to choose EGFR-tyrosine kinase inhibitors (TKIs) as first-line therapy and defer intracranial radiotherapy (RT). …”
Get full text

A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy by Jue Zhang, Zhipeng Qu, Xi Xiao, David L. Adelson, Funeng Wang, Aisheng Wei, Yuka Harata-Lee, Jian Cui, Dongying He, Le Xie, Lingling Sun, Jing Li, Zijing Huang, Thazin Aung, Hong Yao, Lizhu Lin

“…Background: The incidence and mortality of lung cancer are high, and treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the preferred first-line treatment for patients suffering from non-small cell lung cancer (NSCLC) with EGFR mutations. …”
Get full text

Serum Pharmacochemistry and Network Pharmacology Reveal Active Compounds and Mechanisms of the Huaxian Formula in Alleviating Radiation-Induced Pulmonary Fibrosis by Gong C, Chen J, Zou P, Fang Z, Quan L, Wang J, Yin J, Lin B, Lang J, Chen M

“…Overlapping these compounds with 991 RIPF-related genes yielded 127 genes primarily associated with the PI3K-Akt signaling pathway, EGFR tyrosine kinase inhibitor resistance, and the MAPK signaling pathway. …”
Get full text

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib by Jing Zhang, Zequn Wang, Xihua Wei, Mengyuan Han, Ribai Yan, Lijie Ma, Yan Pan

“…Several studies have indicated that sphingosine kinase 1 (SPHK1) plays a regulatory role in epidermal growth factor receptor (EGFR) signaling, and its elevated expression may be associated with resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Furthermore, the catalytic product of SPHK1, sphingosine 1-phosphate (S1P), along with its receptor, sphingosine 1-phosphate receptor 3 (S1PR3), plays a regulatory role in the function of the EGFR. …”
Get full text

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy by Tian He, Bin Xu, Lu-Na Wang, Zi-Yi Wang, Huan-Chen Shi, Cheng-Jie Zhong, Xiao-Dong Zhu, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun, Bo Hu, Cheng Huang

“…A training cohort of 93 patients received atezolizumab plus bevacizumab (T + A), while a validation cohort of 175 patients underwent treatment with tyrosine kinase inhibitors (TKIs) combined with anti-PD-(L)1 therapy. …”
Get full text

Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma by Yaya Chu, Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose, Alyssa S. Mendelowitz, Keira Foley, Mehmet F. Ozkaynak, Wen Luo, Timothy P. Cripe, Dean A. Lee, Kevin A. Cassady, Mitchell S. Cairo

“…Novel therapies are desperately needed. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is highly expressed on NB. …”
Get full text

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer by Vesna Ćeriman Krstić, Dragana Jovanović, Natalija Samardžić, Milija Gajić, Jelena Kotur Stevuljević, Aleksandra Klisic, Ivan Soldatović, Damir Radončić, Marina Roksandić Milenković, Biljana Šeha, Nikola Čolić, Katarina Lukić, Milan Savić

“…Materials and Methods: Blood samples from 35 patients with EGFR-mutated (EGFRmut) adenocarcinoma who achieved disease control with EGFR tyrosine kinase inhibitor (EGFR TKI) therapy were collected for sPD-L1 analysis. …”
Get full text

Radiogenomics and machine learning predict oncogenic signaling pathways in glioblastoma by Abdul Basit Ahanger, Syed Wajid Aalam, Tariq Ahmad Masoodi, Asma Shah, Meraj Alam Khan, Ajaz A. Bhat, Assif Assad, Muzafar Ahmad Macha, Muzafar Rasool Bhat

“…Disruptions in various oncogenic signaling pathways, such as Receptor Tyrosine Kinase (RTK)-Ras-Extracellular signal-regulated kinase (ERK) signaling, Phosphoinositide 3- Kinases (PI3Ks), tumor protein p53 (TP53), and Neurogenic locus notch homolog protein (NOTCH), contribute to the development of different tumor types, each exhibiting distinct morphological and phenotypic features that can be observed at a microscopic level. …”
Get full text

Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data St... by Puco K, Notland CS, Szulkin R, Jonasson C, Beisland C, Johannesen TB, Solli O, Oldenburg J, Heinrich D

“…The results may provide additional information on the benefits of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in clinical practice.Patients and Methods: We performed a longitudinal, retrospective, non-interventional cohort study using data from four national registries. …”
Get full text

Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastases from gastrointestinal stromal tumors by Li Liu, Bing Wang, Zhong-Yi Zhang, Song Wang, Hao Wu, Hong Wang, Wei Wu, Kun Yan, Wei Yang

“…Based on the univariate analysis, the number of metastatic tumors and tyrosine kinase inhibitors(TKI) therapy before RFA were prognostic factors for HPFS. …”
Get full text

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab by Meng Wu, Claudia A.M. Fulgenzi, Antonio D’Alessio, Alessio Cortellini, Ciro Celsa, Giulia F. Manfredi, Bernardo Stefanini, Y. Linda Wu, Yi-Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei-Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang

“…In the second line, 155 patients were treated with tyrosine kinase inhibitors (TKIs), 45 with immune checkpoint inhibitor (IO)-based regimens, and 3 had missing data. …”
Get full text

Non-small Cell Lung Cancer Cell Line PC-9 Drug-resistant Mutant Cell Line 
Establishment and Validation of Their Sensitivity to EGFR Inhibitors by Tao HU, Yang LOU, Mingbo SU

“…Small-molecule EGFR-tyrosine kinase inhibitors (TKIs) serve as first-line therapeutic agents for the treatment of EGFR-mutated NSCLC. …”
Get full text

Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb Euphorbia thymifolia Linn [ver... by ShamaPrasada K, Reshma Kumarchandra, Vasavi Kumblekar, K Sreedhara Ranganath Pai, Suman Manandhar, Sharada Rai, Rajeshwari Shastry

“…Methods ME.ET was subjected to GC-MS analysis to screen the phytoconstituents, and the identified compounds were docked with protein targets such as extracellular signal-regulated kinases (ERK1), a serine/threonine kinase-1(AKT1), human epidermal growth factor 2 (HER2), estrogen receptor (ER), maternal embryonic leucine zipper kinase (MELK), polo-like kinase-1(PLK1), and protein tyrosine kinase (PTK6). Compounds with good docking scores were further subjected to dynamic studies to understand the protein ligand binding stability, ligand pathway calculation, and molecular mechanics energies combined with Poisson-Boltzmann (MM/PBSA) calculations using the Schrodinger suite. …”
Get full text

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment by Bassel Alsaed, Linh Lin, Jieun Son, Jiaqi Li, Johannes Smolander, Timothy Lopez, Pinar Ö. Eser, Atsuko Ogino, Chiara Ambrogio, Yoonji Eum, Tran Thai, Haiyun Wang, Eva Sutinen, Hilma Mutanen, Hanna Duàn, Nina Bobik, Kristian Borenius, William W. Feng, Behnam Nabet, Satu Mustjoki, Sanna Laaksonen, Benjamin K. Eschle, Michael J. Poitras, David Barbie, Ilkka Ilonen, Prafulla Gokhale, Pasi A. Jänne, Heidi M. Haikala

“…Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used to treat non-small cell lung cancers with EGFR mutations, but drug resistance often emerges. …”
Get full text

Liquid chromatography-tandem mass spectrometry for the quantification of ripretinib and its metabolites DP-5439 in human plasma by Jiahui Lin, Jiahui Lin, Aiting Jiang, Juntao Zheng, Jingjing Wu, Hao Li, Hao Li, Shirong Cai, Yulong He, Xiao Chen, Guoping Zhong, Ke-Jing Tang, Ke-Jing Tang, Xinhua Zhang, Yanzhe Xia

“…BackgroundRipretinib, a broad-spectrum tyrosine kinase inhibitor, has been approved for the treatment of advanced gastrointestinal stromal tumors in adult patients. …”
Get full text

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial by Pavlos Msaouel, Kai Yu, Ying Yuan, Jianfeng Chen, Xinmiao Yan, Menuka Karki, Fei Duan, Rahul A. Sheth, Priya Rao, Kanishka Sircar, Amishi Y. Shah, Amado J. Zurita, Giannicola Genovese, Min Li, Chih-Chen Yeh, Minghao Dang, Guangchun Han, Yanshuo Chu, Max Hallin, Peter Olson, Rui Yang, Daniela Slavin, Hirak Der-Torossian, Curtis D. Chin, Nizar M. Tannir, Linghua Wang, Jianjun Gao

“…Abstract We conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. …”
Get full text

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation by Chang Dong Yeo, Dong Won Park, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, Chang‐Min Choi, In‐Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young‐Chul Kim, Tae Won Jang, Kye Young Lee, Seung Hun Jang, Seung Joon Kim, for the Korean EGFR Registry Investigators

“…Moreover, it will investigate various aspects, including the safety and efficacy of a new third‐generation EGFR tyrosine kinase inhibitor (TKI), lazertinib, approved for both first‐ and second‐line treatments. …”
Get full text

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma by Yuan Yao, Yiyi Yan, Vera J. Suman, Allan B. Dietz, Courtney L. Erskine, Anastasios Dimou, Svetomir N. Markovic, Svetomir N. Markovic, Robert R. McWilliams, Heather N. Montane, Matthew S. Block, Matthew S. Block

“…The small molecule ibrutinib is a dual-target agent that inhibits Bruton’s Tyrosine Kinase (BTK) and Interleukin-2-inducible T-cell Kinase (ITK), a key regulator of Th2 immunity. …”
Get full text

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis by Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

“…Abstract Background Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) remains a significant hurdle for patients with EGFR‐mutated non‐small cell lung cancer (NSCLC), particularly those lacking the EGFRT790M. …”
Get full text

Non-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report by Mohamad Hadhud, Johnathan Arnon, Anat Hershko-Moshe, Adi Hollander, Noa Hurvitz-Lehmann, Assaf Potruch, Henny Azmanov, Rottem Kuint, Nurith Hiller, Elie Picard, Naama Sebbag-Sznajder, Shira Leebhoff, Michael Wilschanski, Myriam Grunewald, Liron Birimberg-Schwartz, Malena Cohen-Cymberknoh

“…Following treatment with a targeted tyrosine kinase inhibitor (TKI) there was a rapid tumor regression, however, his dyspnea and hypoxemia subsequently worsened. …”
Get full text